Comprehensive Cell-free Tumor DNA Liquid Biopsy
When cells die, their contents are released into the bloodstream. While healthy individuals also shed genomic materials, known as cell-free DNA, into the bloodstream, only individuals with cancer will have a percentage of cell-free circulating DNA that is tumor derived (ctDNA). ctDNA is found when tumors shed their genomic materials into the bloodstream.
A Liquid Biopsy is a non-invasive sampling of the blood for certain characteristics, such as ctDNA. Because of its non-invasive nature, it does not carry the risk of surgery that is associated with tissue biopsies.
It usually involves simple blood draw of up to two tubes of blood (about 10ml each). The specimen is then sent to a clinical laboratory for the detection of specific tumor mutations that may direct therapy for the patient.
The following is a list of tumor types known to release ctDNA into the bloodstream:
- Head & Neck
- Pancreatic Ductal
- Renal Cell Carcinoma
Asia Genomics offers Guardant360™, the world’s first—and only—comprehensive ctDNA Liquid Biopsy. Guardant360™ requires two 10ml tubes of blood, and takes about three weeks to complete.